Venus Medtech (Hangzhou) Inc. Stock
Equities
2500
CNE100003PJ8
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.62 HKD | -0.71% | -.--% | -.--% |
May. 13 | Venus Medtech Board Receives Internal Control Review Report from Consultant | MT |
Apr. 01 | Venus Medtech Trims Loss in 2023 as Revenue Grows Nearly 21% | MT |
Sales 2024 * | 730M 101M 788M | Sales 2025 * | 990M 137M 1.07B | Capitalization | 2.26B 312M 2.44B |
---|---|---|---|---|---|
Net income 2024 * | -293M -40.48M -316M | Net income 2025 * | 38M 5.25M 41.01M | EV / Sales 2024 * | 3.26 x |
Net Debt 2024 * | 125M 17.29M 135M | Net Debt 2025 * | 463M 63.96M 500M | EV / Sales 2025 * | 2.75 x |
P/E ratio 2024 * |
-7.89
x | P/E ratio 2025 * |
-56.5
x | Employees | 865 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 73.87% |
1 day | -0.71% |
Managers | Title | Age | Since |
---|---|---|---|
Hou-Sen Lim
CEO | Chief Executive Officer | 50 | 16-11-30 |
Fei Wang
DFI | Director of Finance/CFO | 47 | 23-01-03 |
Meirong Liu
BRD | Director/Board Member | 47 | 17-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Hou-Sen Lim
CEO | Chief Executive Officer | 50 | 16-11-30 |
Ting Yuk Wu
CHM | Chairman | 69 | 18-11-25 |
Wei Wang
BRD | Director/Board Member | 41 | 18-11-25 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 112 M€ | +4.09% | - | |
0.00% | 4 M€ | -4.41% | - | |
0.00% | 34 M€ | +4.20% | - |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-.--% | 315M | |
+14.00% | 129B | |
-7.56% | 10.98B | |
-5.82% | 8.22B | |
+42.13% | 5.76B | |
-27.26% | 4.41B | |
+7.45% | 3.41B | |
-13.71% | 2.7B | |
-10.70% | 2.1B | |
-14.30% | 1.91B |
- Stock Market
- Equities
- 2500 Stock